Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biomarker study raises hopes for Alzheimer's blood test

This article was originally published in Scrip

Executive Summary

Research led by UK company Proteome Sciences and King's College London could lead to a clinical blood test for Alzheimer's disease within five years, and, more immediately, could be helpful in selecting patients for clinical trials of new drugs for the condition. Given the enormous failure rate for drug trials in this indication, it is thought that recruiting patients to drug trials earlier in the disease process before irreversible damage is caused could prove more effective, especially as it is thought that Alzheimer's can be asymptomatic for up to ten years.

You may also be interested in...



Deals Shaping The Medtech And Diagnostics Industry, December 2022

Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in November 2022. Data provided by Citeline's Biomedtracker.

Executives On The Move: Allergy Therapeutics, Solid Biosciences and More

Recent executive changes in the industry include C-suite changes at Solid Biosciences and Merck & Co. Meanwhile, new directors were appointed at Allergy Therapeutics and Synairgen.

Mirati Forges Path Forward For Adagrasib In mNSCLC Despite Lukewarm Preliminary Early-Stage Data

The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC025760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel